|
1
|
Blinova E, Turovsky E, Eliseikina E, Igrunkova A, Semeleva E, Golodnev G, Termulaeva R, Vasilkina O, Skachilova S, Mazov Y, Zhandarov K, Simakina E, Belanov K, Zalogin S, Blinov D. Novel Hydroxypyridine Compound Protects Brain Cells against Ischemic Damage In Vitro and In Vivo. Int J Mol Sci 2022; 23:12953. [PMID: 36361739 PMCID: PMC9655885 DOI: 10.3390/ijms232112953] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 10/21/2022] [Accepted: 10/21/2022] [Indexed: 09/29/2023] Open
Abstract
A non-surgical pharmacological approach to control cellular vitality and functionality during ischemic and/or reperfusion-induced phases of strokes remains extremely important. The synthesis of 2-ethyl-6-methyl-3-hydroxypyridinium gammalactone-2,3-dehydro-L-gulonate (3-EA) was performed using a topochemical reaction. The cell-protective effects of 3-EA were studied on a model of glutamate excitotoxicity (GluTox) and glucose-oxygen deprivation (OGD) in a culture of NMRI mice cortical cells. Ca2+ dynamics was studied using fluorescent bioimaging and a Fura-2 probe, cell viability was assessed using cytochemical staining with propidium iodide, and gene expression was assessed by a real-time polymerase chain reaction. The compound anti-ischemic efficacy in vivo was evaluated on a model of irreversible middle cerebral artery (MCA) occlusion in Sprague-Dawley male rats. Brain morphological changes and antioxidant capacity were assessed one week after the pathology onset. The severity of neurological disorder was evaluated dynamically. 3-EA suppressed cortical cell death in a dose-dependent manner under the excitotoxic effect of glutamate and ischemia/reoxygenation. Pre-incubation of cerebral cortex cells with 10-100 µM 3-EA led to significant stagnation in Ca2+ concentration in a cytosol ([Ca2+]i) of neurons and astrocytes suffering GluTox and OGD. Decreasing intracellular Ca2+ and establishing a lower [Ca2+]i baseline inhibited necrotic cell death in an acute experiment. The mechanism of 3-EA cytoprotective action involved changes in the baseline and ischemia/reoxygenation-induced expression of genes encoding anti-apoptotic proteins and proteins of the oxidative status; this led to inhibition of the late irreversible stages of apoptosis. Incubation of brain cortex cells with 3-EA induced an overexpression of the anti-apoptotic genes BCL-2, STAT3, and SOCS3, whereas the expression of genes regulating necrosis and inflammation (TRAIL, MLKL, Cas-1, Cas-3, IL-1β and TNFa) were suppressed. 3-EA 18.0 mg/kg intravenous daily administration for 7 days following MCA occlusion preserved rats' cortex neuron population, decreased the severity of neurological deficit, and spared antioxidant capacity of damaged tissues. 3-EA demonstrated proven short-term anti-ischemic activity in vivo and in vitro, which can be associated with antioxidant activity and the ability to target necrotic and apoptotic death. The compound may be considered a potential neuroprotective molecule for further pre-clinical investigation.
Collapse
Affiliation(s)
- Ekaterina Blinova
- Department of Clinical Anatomy and Operative Surgery, Department of Pharmaceutics Technology and Pharmacology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia
- Department of Fundamental Medicine, National Research Nuclear University MEPHI, 31, Kashirskoe Highway, 115409 Moscow, Russia
| | - Egor Turovsky
- Institute of Cell Biophysics of the Russian Academy of Sciences, Federal Research Center “Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences”, 3 Institutskaya Street, 142290 Pushchino, Russia
| | - Elena Eliseikina
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia
| | - Alexandra Igrunkova
- Department of Clinical Anatomy and Operative Surgery, Department of Pharmaceutics Technology and Pharmacology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia
| | - Elena Semeleva
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia
| | - Grigorii Golodnev
- Department of Clinical Anatomy and Operative Surgery, Department of Pharmaceutics Technology and Pharmacology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia
| | - Rita Termulaeva
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia
| | - Olga Vasilkina
- Department of Fundamental Medicine, National Research Nuclear University MEPHI, 31, Kashirskoe Highway, 115409 Moscow, Russia
| | - Sofia Skachilova
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia
| | - Yan Mazov
- Department of Clinical Anatomy and Operative Surgery, Department of Pharmaceutics Technology and Pharmacology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia
| | - Kirill Zhandarov
- Department of Clinical Anatomy and Operative Surgery, Department of Pharmaceutics Technology and Pharmacology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia
| | - Ekaterina Simakina
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia
| | - Konstantin Belanov
- Department of Pharmaceutical Technology and Pharmacology, Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation, 8/2 Petrovsky Blvd, 127051 Moscow, Russia
| | - Saveliy Zalogin
- Department of Clinical Anatomy and Operative Surgery, Department of Pharmaceutics Technology and Pharmacology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia
| | - Dmitrii Blinov
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia
| |
Collapse
|
|
2
|
Blinova E, Pakhomov D, Shimanovsky D, Kilmyashkina M, Mazov Y, Demura T, Drozdov V, Blinov D, Deryabina O, Samishina E, Butenko A, Skachilova S, Sokolov A, Vasilkina O, Alkhatatneh BA, Vavilova O, Sukhov A, Shmatok D, Sorokvasha I, Tumutolova O, Lobanova E. Cerium-Containing N-Acetyl-6-Aminohexanoic Acid Formulation Accelerates Wound Reparation in Diabetic Animals. Biomolecules 2021; 11:biom11060834. [PMID: 34205061 PMCID: PMC8230275 DOI: 10.3390/biom11060834] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 05/29/2021] [Accepted: 06/01/2021] [Indexed: 01/05/2023] Open
Abstract
Background: The main goal of our study was to explore the wound-healing property of a novel cerium-containing N-acethyl-6-aminohexanoate acid compound and determine key molecular targets of the compound mode of action in diabetic animals. Methods: Cerium N-acetyl-6-aminohexanoate (laboratory name LHT-8-17) as a 10 mg/mL aquatic spray was used as wound experimental topical therapy. LHT-8-17 toxicity was assessed in human skin epidermal cell culture using (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A linear wound was reproduced in 18 outbred white rats with streptozotocin-induced (60 mg/kg i.p.) diabetes; planar cutaneous defect was modelled in 60 C57Bl6 mice with streptozotocin-induced (200 mg/kg i.p.) diabetes and 90 diabetic db/db mice. Firmness of the forming scar was assessed mechanically. Skin defect covering was histologically evaluated on days 5, 10, 15, and 20. Tissue TNF-α, IL-1β and IL-10 levels were determined by quantitative ELISA. Oxidative stress activity was detected by Fe-induced chemiluminescence. Ki-67 expression and CD34 cell positivity were assessed using immunohistochemistry. FGFR3 gene expression was detected by real-time PCR. LHT-8-17 anti-microbial potency was assessed in wound tissues contaminated by MRSA. Results: LHT-8-17 4 mg twice daily accelerated linear and planar wound healing in animals with type 1 and type 2 diabetes. The formulated topical application depressed tissue TNF-α, IL-1β, and oxidative reaction activity along with sustaining both the IL-10 concentration and antioxidant capacity. LHT-8-17 induced Ki-67 positivity of fibroblasts and pro-keratinocytes, upregulated FGFR3 gene expression, and increased tissue vascularization. The formulation possessed anti-microbial properties. Conclusions: The obtained results allow us to consider the formulation as a promising pharmacological agent for diabetic wound topical treatment.
Collapse
MESH Headings
- Administration, Topical
- Aminocaproates/administration & dosage
- Aminocaproates/metabolism
- Animals
- Cerium/administration & dosage
- Cerium/metabolism
- Diabetes Mellitus, Experimental/drug therapy
- Diabetes Mellitus, Experimental/metabolism
- Diabetes Mellitus, Experimental/pathology
- Diabetes Mellitus, Type 1/drug therapy
- Diabetes Mellitus, Type 1/metabolism
- Diabetes Mellitus, Type 1/pathology
- Diabetes Mellitus, Type 2/drug therapy
- Diabetes Mellitus, Type 2/metabolism
- Diabetes Mellitus, Type 2/pathology
- Female
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Rats
- Wound Healing/drug effects
- Wound Healing/physiology
Collapse
Affiliation(s)
- Ekaterina Blinova
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
- Department of Morphology, National Research Nuclear University MEPHI, 31 Kashirskoe Highway, 115409 Moscow, Russia
| | - Dmitry Pakhomov
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Denis Shimanovsky
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Marina Kilmyashkina
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Yan Mazov
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Tatiana Demura
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Vladimir Drozdov
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Dmitry Blinov
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraya Kupavna, Russia; (E.S.); (S.S.); (I.S.)
- Correspondence: ; Tel.: +7-927-197-1422
| | - Olga Deryabina
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Elena Samishina
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraya Kupavna, Russia; (E.S.); (S.S.); (I.S.)
| | - Aleksandra Butenko
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Sofia Skachilova
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraya Kupavna, Russia; (E.S.); (S.S.); (I.S.)
| | - Alexey Sokolov
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Olga Vasilkina
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Bashar A. Alkhatatneh
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Olga Vavilova
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Andrey Sukhov
- Department of Clinical Anatomy and Operative Surgery, Department of Pathological Anatomy, Institute for Regenerative Medicine, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia; (E.B.); (D.S.); (Y.M.); (T.D.); (V.D.); (A.B.); (A.S.); (O.V.); (A.S.)
| | - Daniil Shmatok
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Ilya Sorokvasha
- Laboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraya Kupavna, Russia; (E.S.); (S.S.); (I.S.)
| | - Oxana Tumutolova
- Laboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia; (D.P.); (M.K.); (O.D.); (O.V.); (B.A.A.); (D.S.); (O.T.)
| | - Elena Lobanova
- Department of Pharmacology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 20/1 Delegatskaya Street, 127473 Moscow, Russia;
| |
Collapse
|
|
3
|
Novikov A, Blinova E, Semeleva E, Karakhanjan K, Mironov M, Blinov D, Krainova Y, Pakhomov D, Vasilkina O, Samishina E. On local anesthetic action of some dimethylacetamide compounds. RRP 2018. [DOI: 10.3897/rrpharmacology.4.31440] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The study aim was to explore local anesthetic properties of some tertiary and quaternary derivatives of dimethylacetamide.
Materials and methods. The study was performed on white laboratory mice and rats of both sexes, male Agouti guinea pigs, and isolated sciatic nerves of lake frog. In the focus of the study there were two quaternary and eight tertiary compounds of dimethylacetamide with substituted anion with some amino and carbonic acids residue. A local anesthetic property was predicted by computational analysis. Acute toxicity of the most promising substances was studied in mice through subcutaneous route. Local anesthetic activity of tertiary compounds LKhT-3-00, LKhT-4-00 and quaternary LKhT-12-02 was studied on models of terminal, infiltration and conduction anesthesia. The influence of substances on mixed nerve conduction was investigated on lake frog’s isolated sciatic nerves.
Results and discussion. The greatest probability of the local anesthetic activity during computational analysis was estimated for the tertiary derivatives of dimethylacetamide LKhT-3-00 and LKhT-4-00 and for the quaternary compound LKhT-12-02. According to their toxicological profile, the compounds belong to moderately toxic substances (class 3). On the model of terminal and infiltration anesthesia, substances LKhT-3-00 and LKhT-4-00 at concentrations of 0.5-1% rapidly cause deep and prolonged anesthesia. On the models of conduction anesthesia, the quaternary derivative of dimethylacetamide LKhT-12-02 has the greatest analgesic effect. The duration of the effect of the substance is over 3 hours. All the investigated compounds block sciatic nerve conduction. The longest effect is registered for LKhT-12-02.
Conclusions. Dimethylacetamide derivatives at concentrations of 0.5-1.0% exhibit a local anesthetic activity, and are effective for terminal, conduction and infiltration anesthesia. Their effect is due to blockade of nerve conduction.
Collapse
|